Article
Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733.
PloS one - 1 Jan 2017
Crawford Emily D, Quan Jenai, Horst Jeremy A, Ebert Daniel, Wu Wesley, DeRisi Joseph L
Abstract excerpt
Genetic manipulation of the deadly malaria parasite Plasmodium falciparum remains challenging, but the rise of CRISPR/Cas9-based genome editing tools is increasing the feasibility of altering this parasite's genome in order to study its biology. Of particular interest is the investigation of drug targets and drug resistance mechanisms, which have major implications for fighting malaria. We present a new method...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.